Standing here today $11 per share ($3 billion) seems high, however, that all could change quickly depending what happens on the viral side. If the viral side shows immediate promise (should receive data much faster due to quicker results) and we start seeing revenue (i.e stockpiling) who knows. If viral starts to prove it self then BP could pay more for company with viral as given with promising cancer side on the come.
Honestabe: I don't think a 3 billion dollar market cap is too preposterous at all. I think its way too low. I'm basing that on Bristol Myers Squibb's offer to purchase Medarex for $16 per share (source Wikipedia and matches current share price). That would be ~2.1 billion for what appears to be a single drug pipeline for melanoma and prostate and still in trials. Reading about the trial results in Wikipedia doesn't appear to be all that impressive although the drug seems be doing well for prostate cancers. PPHM is testing their drugs in the two largest cancer populations - breast and lung - and are having very good results to date. I would think that any deal for PPHM's pipeline less than established deals like the BMS offer for Mearex would be ridiculously under priced.
I don't know how to price a company but this example would seem to be a good starting point.
I think PPHM's problem is their pipeline is too good and no one can afford them. Boy will I probably hear back on that statement. Probably the kind of statement that will provide me and education - wanted or not.
News 
Market Data 
Discover 
